优化血友病A基因治疗前后的肝脏健康
血友病A基因治疗依赖腺相关病毒(AAV)载体和肝特异性启动子,需健康肝细胞功能以实现安全持久的因子VIII(FVIII)活性提升。本文阐述肝脏健康影响基因治疗的生物学基础,并提供治疗前后评估、监测和管理肝脏健康的实用临床指导。
要点
- 肝细胞健康是血友病A基因治疗安全有效的关键因素。
- 基因治疗可能诱导对转导肝细胞的免疫反应,需密切监测肝功能和因子水平。
- 高风险患者应每6个月进行肝细胞癌影像筛查,推荐所有血友病A基因治疗接受者筛查。
核心结论
- 肝细胞健康是血友病A基因治疗安全成功的重要方面,治疗前后需评估、监测和管理肝脏健康。
研究设计与样本
- 本文为综述,描述肝脏健康影响血友病A基因治疗的生物学基础,并提供实用临床指导。
主要发现
- 许多血友病A患者有当前或既往慢性丙型肝炎病毒感染、代谢功能障碍相关脂肪性肝病或脂肪性肝炎,或其他可能损害AAV介导基因治疗疗效和安全性的状况。
- 基因治疗可能诱导对转导肝细胞的免疫反应,导致肝脏炎症和FVIII活性降低;免疫反应可用免疫抑制治疗,但需密切监测肝功能检查和因子水平。
- 基因治疗相关的肝细胞癌长期风险未知。
关键数值与推荐
- 高风险患者应每6个月进行肝细胞癌影像筛查,优选每6个月一次,并推荐所有血友病A基因治疗接受者进行筛查。
临床怎么用
- 治疗前评估肝脏健康状况,治疗后密切监测肝功能和因子水平,高风险患者每6个月影像筛查肝细胞癌,所有基因治疗接受者推荐筛查。
局限性
- 基因治疗相关的肝细胞癌长期风险未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gene therapy for severe hemophilia A uses an adeno-associated virus (AAV) vector and liver-specific promoters that depend on healthy hepatocyte function to achieve safe and long-lasting increases in factor VIII (FVIII) activity. Thus, hepatocyte health is an essential aspect of safe and successful gene therapy. Many people living with hemophilia A have current or past chronic hepatitis C virus infection, metabolic dysfunction-associated steatosis or steatohepatitis, or other conditions that may compromise the efficacy and safety of AAV-mediated gene therapy. In addition, gene therapy may induce an immune response to transduced hepatocytes, leading to liver inflammation and reduced FVIII activity. The immune response can be treated with immunosuppression, but close monitoring of liver function tests and factor levels is necessary. The long-term risk of hepatocellular carcinoma associated with gene therapy is unknown. Routine screening by imaging for hepatocellular carcinoma, preferable every 6 months, is essential in patients at high risk and recommended in all recipients of hemophilia A gene therapy. This paper describes our current understanding of the biologic underpinnings of how liver health affects hemophilia A gene therapy, and provides practical clinical guidance for assessing, monitoring, and managing liver health both before and after gene therapy.
引用
- Ragni MV, Mead H, de Jong YP, et al. Optimizing liver health before and after gene therapy for hemophilia A. Blood Adv. 2024. PMID: 38843379. doi:10.1182/bloodadvances.2024013059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。